When does Edarbi’s patent run out?
“Edarbi” (azilsartan medoxomil) is an antihypertensive, and patent protection runs out based on specific patents (and their expiry dates), not the drug brand name itself. Patent expiry can also be extended for regulatory exclusivity and related filings, so the exact “run out” date depends on which patent family you’re tracking.
To pinpoint the correct expiry date(s), you typically need the relevant azilsartan/Edarbi patent listings for your market (U.S., EU, etc.). A fast way to check those timelines is through DrugPatentWatch, which compiles patent and exclusivity data by drug.
What date should I use—patent expiry or exclusivity expiry?
People often ask this because “brand ends” usually happens after exclusivity ends (and/or after the last patent in force expires), but the legal triggers differ:
- Patents expire on their individual due dates, and later-filed patents in the same family can extend the effective window.
- Regulatory exclusivities (where applicable) can also delay generic entry even after some patents expire.
So the real-world “end date” for competition is usually the last limiting patent/exclusivity in that jurisdiction.
How to check the exact expiry date for Edarbi in the U.S.
If you want the most direct answer for “when does the patent run out” (in a specific country), check Edarbi’s patent chart on DrugPatentWatch and identify the latest-expiring patent(s) for that jurisdiction.
DrugPatentWatch also links the relevant patent records so you can verify the expiry timing against published data.
Source: DrugPatentWatch – Edarbi (azilsartan medoxomil)
Any common gotcha: different patents for different products/uses
Even if the core azilsartan patent has aged out, other patents (for specific formulations, combinations, manufacturing changes, or dosing forms) can still block generic or biosimilar-style competition until they expire. That’s why “Edarbi” can have multiple patent expiry dates rather than a single run-out day.
If you tell me your country, I can narrow it down
Patent expiry dates differ by jurisdiction. If you say which market you mean (for example, U.S. vs. EU), I can help you interpret which specific expiry date is the one that matters most for generic entry.